Center for Addiction Medicine

Smoking Cessation Medications Do Not Appear to Increase Risk of Neuropsychiatric Side Effects

The Lancet

The smoking cessation medications varenicline and bupropion do not appear to increase the incidence of serious neuropsychiatric side effects compared to placebo, according to a study published in The Lancet in April, this paper provides details of the FDA-requested study that involved over 8,000 people. Read about it in the Lancet and ScienceDaily. Laurie Zawertailo comments on the study in the Lancet.